Inclusion Criteria:
* 1\. Ability to provide informed consent in English.
* 2\. Provision of signed and dated informed consent form.
* 3\. Stated willingness to comply with all study procedures and availability for the duration of the study.
* 4\. Male and female participants aged 21 to 65 years.
* 5\. For women of childbearing potential, i.e., not surgically sterilized (tubal ligation/hysterectomy) or not post-menopausal (no menstrual period for greater than 12 months): (a.) Must have a negative urine pregnancy test at screening and immediately before test sessions. (b.) Must be willing to use a medically acceptable and effective birth control method while participating in the study.
* 6\. Have no clinically significant contraindications, in the judgment of the SI/study physician, for study participation (based on self-reported medical history and physical examination)
* 7\. Safe transportation plan after the dosing session (e.g., a designated drive, or pre-arranged transportation).
For AUD groups (encompassing persons with AUD-only and persons with AUD+CP):
* 1\. Meet DSM-5 criteria for alcohol use disorder.
* 2\. Have experienced at least one heavy drinking episode in the past 30 days (defined as consuming more than four standard drink units (SDU) for men and more than three SDU for women).
For CP groups (encompassing persons with CP-only and persons with AUD+CP):
\- 1. Have high-impact, non-cancer low back pain that has persisted for at least three months, occurs on most days, and limits life or work activities.
For healthy individuals:
* 1\. No current or lifetime DSM-5 diagnosis of substance use disorder (excluding tobacco use disorder).
* 2\. Alcohol use within normal NIAAA-defined limits (i.e., 14 or fewer drinks per week for men or 7 or fewer drinks per week for women; with no binge drinking episodes in the past 3 months).
* 3\. No chronic pain as defined for CP groups.
* 4\. No regular use of pain medications or psychotropic medications.
Exclusion Criteria:
* 1\. Meeting DSM-5 criteria for any substance use disorders other than alcohol and/or tobacco use disorder within the past year.
* 2\. Currently seeking treatment for AUD.
* 3\. Currently experiencing alcohol withdrawal, defined as a Clinical Institute Withdrawal Assessment of Alcohol Scale, Revised (CIWA-Ar) score greater than 8.
* 4\. Recent history of complicated alcohol withdrawal, alcohol withdrawal seizures, or delirium tremens.
* 5\. Current physiological alcohol dependence requiring a higher level of care (e.g., detox) as determined by the study physician conducting a physical examination.
* 6\. Current bipolar disorder, primary psychotic disorders, or mood disorders with psychotic features.
* 7\. Current suicidal ideation, intent, or plan as indicated on the Columbia Suicide Severity Rating Scale (C-SSRS).
* 8\. Females who are pregnant, nursing, or planning to become pregnant during study participation.
* 9\. Positive pregnancy test or lack of birth control measures in women of childbearing potential.
* 10\. Clinically major medical disorders including: liver disease, heart disease, cardiac disease, or other medical conditions that the SI or study physician deems contraindicated for participation.
* 11\. Clinically significant medical conditions including hepatic ascites (bilirubin greater than 10% above the upper limit of normal \[ULN\], liver function tests \[LFT\] greater than 3x ULN), or renal impairment as measured by BUN/Creatinine.
* 12\. Neurological conditions that may change the response to nociceptive stimuli (e.g., stroke, neuropathy), as evidenced by a neuro-sensory examination.
* 13\. Contraindications for exposure to nociceptive stimuli, such as untreated hypertension.
* 14\. Major neurocognitive disorders (e.g., dementia, delirium, amnestic) precluding participation, as evidenced by a clinical examination.
* 15\. Currently taking the following medications: (a.) Opioids; (b.) Benzodiazepines; (c.) Medications for alcoholism; (d.) Psychotropic medications that promote sedation, including sedative/hypnotics, barbiturates, sedative antidepressants, and triptans; (e.) Antihypertensive medications; (f.) Centrally acting alpha-2 adrenergic agonists or alpha-1 adrenergic antagonists prescribed for any indication.
* 16\. For non-opioid analgesics (e.g., NSAIDs, gabapentinoids, cyclobenzaprine), participants must meet the following medication stabilization criteria: no start/stop or 25% or greater dose change within 14 days before the first test session, and no as-needed use within 12 hours before each test session.
* 17\. Positive urine drug screen for illicit substances prior to the start of each test session.
* 18\. Positive THC saliva assay and/or urine THC concentration greater than 50 ng/mL prior to the start of each test session assessed using a quantitative point-of-care urine 11-nor-9-carboxy-THC concentration test.
* 19\. Participation in a clinical trial of a pharmacological agent within 30 days prior to screening.
* 20\. Any other condition that, in the investigator's judgment, would compromise safety or ability to complete the study.